Cargando…

Myelosuppression by sunitinib is flt-3 genotype dependent

Detalles Bibliográficos
Autores principales:	van Erp, N P, Mathijssen, R H J, van der Veldt, A A, Haanen, J B, Reyners, A K L, Eechoute, K, Boven, E, Wessels, J A M, Guchelaar, H-J, Gelderblom, H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938256/ https://www.ncbi.nlm.nih.gov/pubmed/20683446 http://dx.doi.org/10.1038/sj.bjc.6605813

Ejemplares similares

Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2009)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
por: van der Veldt, A A M, et al.
Publicado: (2008)

Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
por: Liu, Xiaoyan, et al.
Publicado: (2016)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
por: Diekstra, Meta H. M., et al.
Publicado: (2015)

Marginal increase of sunitinib exposure by grapefruit juice
por: van Erp, Nielka P., et al.
Publicado: (2010)

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype
por: Broekman, M. M. T. J., et al.
Publicado: (2017)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

UGT1A1(*)28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
por: Kweekel, D M, et al.
Publicado: (2008)

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy
por: Warkentin, Alexander A, et al.
Publicado: (2014)

Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry
por: IJzerman, Nikki S., et al.
Publicado: (2020)

Thrombocytopenia and bleeding in myelosuppressed transfusion-dependent patients: a simulation study exploring underlying mechanisms
por: Middelburg, Rutger A, et al.
Publicado: (2018)

Regarding: ‘Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array’
por: Pander, J, et al.
Publicado: (2010)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
por: Kloth, Jacqueline S. L., et al.
Publicado: (2015)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial
por: Schneider, T. C., et al.
Publicado: (2015)

Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?
por: IJzerman, N.S., et al.
Publicado: (2022)

Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
por: Diekstra, Meta H. M., et al.
Publicado: (2022)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2018)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
por: Horn, Kevin P., et al.
Publicado: (2015)

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
por: van Eerden, Ruben A. G., et al.
Publicado: (2023)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease
por: Krens, L. L., et al.
Publicado: (2017)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pabrt554dvik1jler2rpllnfql